Evidence map›Paper›PMID 39960621›Full record

ArticleMikrochimica acta2025

Ti

Ziwei Zou, Yi Chen, Rengang Sun, Boya Shi, Li Jiang, Feixiang Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ziwei ZouCollege of Optical and Electronic Technology, China Jiliang University, Hangzhou, 310018, PR, China.
Yi ChenCollege of Optical and Electronic Technology, China Jiliang University, Hangzhou, 310018, PR, China. chenyi@cjlu.edu.cn.
Rengang SunDepartment of TCM Gynecology, Hangzhou Women's Hospital, Hangzhou, 310008, PR, China.
Boya ShiDepartment of TCM Gynecology, Hangzhou Women's Hospital, Hangzhou, 310008, PR, China.
Li JiangDepartment of TCM Gynecology, Hangzhou Women's Hospital, Hangzhou, 310008, PR, China.
Feixiang HuangDepartment of TCM Gynecology, Hangzhou Women's Hospital, Hangzhou, 310008, PR, China. fxhuang2009@163.com.

Funding

National Natural Science Foundation of China 52271139Natural Science Foundation of Zhejiang Province LZ22F050004
6 · The paper itself

Abstract

A surface plasmon resonance imaging (SPRi) biosensor is presented which facilitates rapid and sensitive detection of the ovarian cancer biomarker carbohydrate antigens 125 (CA125). The CA125 protein was specifically captured and directly recognized by polyadenylic (polyA)-modified DNA aptamer on the surface of a Au chip. The biosensor demonstrated a linear range of direct detection of CA125 based on SPRi from 20 nM to 0.5 nM, with a detection limit of 0.47 nM. Furthermore, Fe

Indexed as

Biosensing TechniquesCA-125 AntigenSurface Plasmon ResonanceTitaniumAptamers, NucleotideFemaleGoldHumansLimit of DetectionMembrane ProteinsAptamers, NucleotideCA-125 AntigenGoldMembrane ProteinsMUC16 protein, humanTitaniumtitanium carbideBiosensorCA125 proteinFe3O4Gold based sensor chipSurface plasmon resonance imaging (SPRi)Ti3C2

Identifiers

PMID39960621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.